Výsledky vyhledávání - "C. S. Rocha Lima"

Combination study of navitoclax with gemcitabine (G) in patients (pts) with solid tumors

Autor: Rod A. Humerickhouse, Todd A. Busman, Hope E. Uronis, C. S. Rocha Lima, Jianning Yang, Alison M. Graham, Herbert Hurwitz, Kyle D. Holen, James M. Cleary, Geoffrey I. Shapiro, Andrew Krivoshik, Mack Mabry, Catherine Franklin, Alberto J. Montero

Publikováno v: Journal of Clinical Oncology. 29:3067-3067

3067 Background: Navitoclax (ABT-263), a novel BH3 mimetic, binds with high affinity and inhibits multiple antiapoptotic Bcl-2 proteins. Preclinical studies show synergy between navitoclax and G in...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a8e45a1d4c09d91dbae0a734d408dec5
https://doi.org/10.1200/jco.2011.29.15_suppl.3067

Zobrazit plný text záznamu

Pilot study of neoadjuvant FOLFIRINOX in unresectable locally advanced (LA) pancreatic carcinoma (PC)

Autor: Arturo Loaiza-Bonilla, Joe U. Levi, C. S. Rocha Lima, Peter J. Hosein, C. Kawamura, Jessica MacIntyre, Jaime R. Merchan

Publikováno v: Journal of Clinical Oncology. 29:324-324

324 Background: 5-flourouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is superior to gemcitabine in patients (pts) with advanced PC who have a good performance status (Conroy et al, ACCORD 11 trial, ASCO 2010). After the initial data on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c17a3d5e1688e9b3a6e457fb9ad4a505
https://doi.org/10.1200/jco.2011.29.4_suppl.324

Zobrazit plný text záznamu

Effect of the addition of algenpantucel-L immunotherapy to standard adjuvant therapy on survival in patients with resected pancreas cancer

Autor: Jennifer Obel, Mary F. Mulcahy, H. J. Lenz, Jeffrey M. Hardacre, C. S. Rocha Lima, Mark S. Talamonti, Elena G. Chiorean, Charles J. Link, William Small, Howard Safran

Publikováno v: Journal of Clinical Oncology. 29:236-236

236 Background: Pancreatic cancer portends a poor prognosis with ∼4% long-term survival. Among the estimated 20% of patients who have resectable disease, the 1-/3-/5-year survival rates approximate only 70%/30%/18%, even with adjuvant therapy. Bett

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ce47c13f1f86d3a7b33b5434b1d2bcd
https://doi.org/10.1200/jco.2011.29.4_suppl.236

Zobrazit plný text záznamu

Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC)

Autor: C. S. Rocha Lima, J. C. Baranda, J. Wallmark, Y. Choi, S. Royer-Joo, C. C. Portera

Publikováno v: Journal of Clinical Oncology. 29:546-546

546 Background: Drozitumab is a monoclonal antibody that triggers tumor cell apoptosis by selective agonistic interaction with the Apo2 ligand/TNF-related apoptosis-inducing ligand death receptor 5. This study assessed the safety of drozitumab combin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a5322eb55604d4f31ab9aa0389f19f48
https://doi.org/10.1200/jco.2011.29.4_suppl.546

Zobrazit plný text záznamu

Phase II trial of ixabepilone (IXA) plus cetuximab (C) as first-line therapy for advanced pancreatic carcinoma (PC)

Autor: John L. Marshall, M. B. McHenry, C. S. Rocha Lima, Philip A. Philip, Edward H. Lin, J. K. Giguere, C. N. Papageorgio, Miklos L Auber, George P. Kim, Mark M. Zalupski

Publikováno v: Journal of Clinical Oncology. 28:4086-4086

4086 Background: Progress in the management of PC is desperately needed. Non-gemcitabine based regimens are understudied. IXA has demonstrated activity in preclinical PC models including synergisti...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::22ada3c77a37a46d5c1acbcf264c6984
https://doi.org/10.1200/jco.2010.28.15_suppl.4086

Zobrazit plný text záznamu

Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC)

Autor: Michael B. Sawyer, I. Krivelevich, D. P. Rossignol, C. S. Rocha Lima, Anthony B. El-Khoueiry, H. J. Lenz, J. Fan, Syma Iqbal

Publikováno v: Journal of Clinical Oncology. 28:3537-3537

3537 Background: In vitro,E7820, inhibits α2-integrin expression, endothelial cell proliferation, and vascular tube formation. In colorectal cancer xenograft models, the combination of E7820 and ce...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ba21074b7a318001e8fce8f8682d936
https://doi.org/10.1200/jco.2010.28.15_suppl.3537

Zobrazit plný text záznamu

TMS1 as a potential therapeutic target of pancreatic cancer

Autor: C. S. Rocha Lima, Rakesh Singal, Kavitha Ramachandran, Edna Gordian, H. Miller

Publikováno v: Journal of Clinical Oncology. 28:e14614-e14614

e14614 Background: Pancreatic cancer is the fourth leading cause of cancer related deaths in the United States, with an estimated 42,470 new cases and 35,240 deaths in 2009. Advanced pancreatic can...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::88a9048e7b5a34107584a607a1eb0ba4
https://doi.org/10.1200/jco.2010.28.15_suppl.e14614

Zobrazit plný text záznamu

A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC)

Autor: Howard Safran, J. Wiezorek, C. S. Rocha Lima, Lawrence Garbo, Hedy L. Kindler, C. Fuchs, Joe Stephenson, D. Richards, E. G. Feigal, Sarah Bray

Publikováno v: Journal of Clinical Oncology. 28:4035-4035

4035 Background: C, a death receptor 5 agonist, and A, an insulin-like growth factor receptor 1 antagonist, are investigational, fully human monoclonal antibodies with preclinical activity in PC mo...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::89ebbaeefec89d5b16033b578f243e03
https://doi.org/10.1200/jco.2010.28.15_suppl.4035

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání